Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: More than 50% of all patients with colorectal cancer (CRC) develop liver metastases (CLM), a clinical condition characterized by poor prognosis and lack of reliable prognostic markers. Vδ1 cells are a subset of tissue-resident gamma delta (γδ) T lymphocytes endowed with a broad array of antitumor functions and showing a natural high tropism for the liver. However, little is known about their impact in the clinical outcomes of CLM. Methods: We isolated human γδ T cells from peripheral blood (PB) and peritumoral (PT) tissue of 93 patients undergone surgical procedures to remove CLM. The phenotype of freshly purified γδ T cells was assessed by multiparametric flow cytometry, the transcriptional profiles by single cell RNA-sequencing, the functional annotations by Gene Ontology enrichment analyses and the clonotype by γδ T cell receptor (TCR)-sequencing. Results: The microenvironment of CLM is characterized by a heterogeneous immune infiltrate comprising different subsets of γδ tumor-infiltrating lymphocytes (TILs) able to egress the liver and re-circulate in PB. Vδ1 T cells represent the largest population of γδ TILs within the PT compartment of CLM that is greatly enriched in Vδ1 T effector (T EF) cells expressing constitutive high levels of CD69. These Vδ1 CD69+ TILs express a distinct phenotype and transcriptional signature, show high antitumor potential and correlate with better patient clinical outcomes in terms of lower numbers of liver metastatic lesions and longer overall survival (OS). Moreover, intrahepatic CD69+ Vδ1 TILs can egress CLM tissue to re-circulate in PB, where they retain a phenotype, transcriptional signature and TCR clonal repertoires resembling their liver origin. Importantly, even the increased frequencies of the CD69+ terminally differentiated (T EMRA) Vδ1 cells in PB of patients with CLM significantly correlate with longer OS. The positive prognostic score of high frequencies of CD69+ T EMRA Vδ1 cells in PB is independent from the neoadjuvant chemotherapy and immunotherapy regimens administered to patients with CLM prior surgery. Conclusions: The enrichment of tissue-resident CD69+ Vδ1 T EMRA cells re-circulating at high frequencies in PB of patients with CLM limits tumor progression and represents a new important clinical tool to either predict the natural history of CLM or develop alternative therapeutic protocols of cellular therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232
γδ T cell effector functions: a blend of innate programming and acquired plasticity
Bonneville, M., O'Brien, R. L., & Born, W. K. (2010) · Nature Reviews Immunology · doi:10.1038/nri2781 · Cited by 952
CD69: from activation marker to metabolic gatekeeper
Cibrián, D., & Sánchez‐Madrid, F. (2017) · European Journal of Immunology · doi:10.1002/eji.201646837 · Cited by 948 · cited 2×
“Taken together, these findings demonstrate that CD69 + V δ 1 T EF cells in CLM specimens limit the metastatic progression of CRC to liver and can also serve as a reliable prognostic marker in ‘liquid biopsies’ to identify those patients with better clinical outcomes.”
Location, location, location: Tissue resident memory T cells in mice and humans
Szabo, P. A., Miron, M., & Farber, D. L. (2019) · Science Immunology · doi:10.1126/sciimmunol.aas9673 · Cited by 651 · cited 1×
“Taken together, these findings demonstrate that CD69 + V δ 1 T EF cells in CLM specimens limit the metastatic progression of CRC to liver and can also serve as a reliable prognostic marker in ‘liquid biopsies’ to identify those patients with better clinical outcomes.”
Silva-Santos, B., Serre, K., & Norell, H. (2015) · Nature reviews. Immunology · doi:10.1038/nri3904 · Cited by 565
γδ T cells in tissue physiology and surveillance
Ribot, J. C., Lopes, N., & Silva-Santos, B. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00452-4 · Cited by 532
Brummelman, J., Mazza, E. M. C., Alvisi, G., Colombo, F. S., Grilli, A., Mikulak, J., Mavilio, D., Alloisio, M., Ferrari, F., Lopci, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180684 · Cited by 334
Self-citationLi, F., Hao, X., Chen, Y., Bai, L., Gao, X., Lian, Z., Wei, H., Sun, R., & Tian, Z. (2017) · Nature Communications · doi:10.1038/ncomms13839 · Cited by 191
Cited by
The emerging roles of γδ T cells in cancer immunotherapy
Mensurado, S., Blanco-Domínguez, R., & Silva-Santos, B. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00722-1 · Cited by 342
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
“In metastatic colorectal cancer, γδT cells still show the ability to limit tumor progression [5].”
BackgroundMarinović, S., Lenartić, M., Mladenić, K., Šestan, M., Kavazović, I., Benić, A., Krapić, M., Rindlisbacher, L., Cokarić Brdovčak, M., Sparano, C., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1599 · Cited by 43
Marzano, P., Balin, S., Terzoli, S., Della Bella, S., Cazzetta, V., Piazza, R., Sandrock, I., Ravens, S., Tan, L., Prinz, I., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1208662 · Cited by 13
“Freshly PBMCs were isolated through Lympholyte®-H Cell Separation density gradient solution (Cedarlane Laboratories, Burlington, North Carolina, USA) according to the manufacturer’s instructions and frozen in Fetal Bovine Serum (FBS, EuroClone) supplemented with 10% of the cryoprotective dimethyl sulfoxide (DMSO, PanR…”
MethodSelf-citation
Metadata
- Authors
- Bruni, E., Cimino, M. M., Donadon, M., Carriero, R., Terzoli, S., Piazza, R., Ravens, S., Prinz, I., Cazzetta, V., Marzano, P., Kunderfranco, P., Peano, C., Soldani, C., Franceschini, B., Colombo, F. S., Garlanda, C., Mantovani, A., Torzilli, G., Mikulak, J., & Mavilio, D.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2022-07
- Volume
- 10
- Issue
- 7
- Pages
- e004579
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W4286267975
- Cited by
- 57
- References
- 9
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. https://app.cochat.ai/papers/10.1136/jitc-2022-004579
- The paper
- Bruni, E., Cimino, M. M., Donadon, M., Carriero, R., Terzoli, S., Piazza, R., Ravens, S., Prinz, I., Cazzetta, V., Marzano, P., Kunderfranco, P., Peano, C., Soldani, C., Franceschini, B., Colombo, F. S., Garlanda, C., Mantovani, A., Torzilli, G., Mikulak, J., & Mavilio, D. (2022). Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-004579
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.